Hospital

Advanced technology can automate many pharmacovigilance tasks to build workflow efficiencies, reduce manual intervention, and free up team members for more strategic activities.

Perhaps the most significant development in the pharmaceutical industry in decades, crops of biosimilars are being approved and are ready for distribution. What lies next, in terms of legislation and the impact on pharmacists, remains to be seen.

This social determinant of health could have the same level of negative impact on health as the experience of racism, poverty, or low education.

Pharmacists' expertise is invaluable to prescribers who are unfamiliar with opioid use disorder treatment protocols.

Investigators found that artificial intelligence chatbots did not consistently provide recommendations for cancer treatment that correspond with NCCN guidelines.

With the help of new and complex algorithms and self-learning models, we are currently privy to what we may look back on as the golden era of AI.

Although the patient demographics are similar for the 3 categories of hemolytic reactions with intravenous immunoglobulin, the reaction with delayed hemolytic transfusion reactions was highest compared to the other 2 hemolytic reactions.

The research was aided by the Decipher Genomics Resource for Intelligent Discovery, which helped derive the gene signatures used during the analysis.

The FDA is the first regulatory agency globally to approve natalizumab-sztn as a biosimilar for natalizumab.

Tom Knight, founder and CEO of Invistics, now part of Wolters Kluwer, discusses the dangers of drug diversion and how this could negatively impact affect patients.

Investigators determined that there needs to be an evaluation of harm caused by pharmacy professionals who are in unique positions on social media, propagating misinformation about COVID-19, vaccines, treatment, masks, and other conspiracy theories.

Participants indicated that they would be more likely to accept PrEP-related information if it was recommended by a trusted person.

The drug is the first approved antiviral COVID-19 treatment that could be used across all stages of liver disease.

Belzutifan also demonstrated statistically significant improvements in objective response rate compared to everolimus for advanced renal cell carcinoma.

In the study, investigators incorporated data from electronic health records and social determinants of health into the model to determine the likelihood in delays when starting cancer therapy.

Notably, 65% of the participants experiencing pain at the 2-month follow up were also experiencing pain at their 12-month follow up, suggesting persistent and long-term pain.

During the phase 1b/2 trials, CAR T-cell therapy demonstrated significant and clinical survival benefits.

Protection of T cells from tumor-induced suppression suggests potential for enhancing efficacy of therapies, with plans to initiate a phase 1/2 clinical trial in patients with advanced breast cancer.

The drug showed statistically significant and clinically meaningful efficacy results across key subgroups.

Patients with pancreatic cancer who took benzodiazepine lorazepam had a shorter progression-free survival than those who took benzodiazepine alprazolam.

Relapses of MIS-C occurred in 2 patients due to rapid tapering of corticosteroids at 2 weeks instead of the standard protocol of 4 to 6 weeks.

It is the first vaccine of its kind to be FDA approved, and it met multiple safety and efficacy standards through clinical trials.

Researchers sought to find a remedy for the development of treatment-resistant depression in patients whose antidepressant treatment has fluctuated in efficacy.

The treatment is the first of its kind to be FDA-approved to treat CHAPLE disease.

The model was the first to incorporate C-reactive protein/albumin ratio and apply LASSO regression analysis to a predictive model for children with Kawasaki disease.

The results differ from previous studies and the predictions of the researchers that the Child Tax Credit would reduce the prevalence of low birth weight among pregnant women across the country.

Opportunities for an additional specialization in molecular pathology may be helpful to train professionals in the real-time interpretation of gene therapy test results.

Based on results from a trial of repotrectinib in patients with ROS1-positive locally advanced or metastatic non-small cell lung cancer, the FDA accepted the New Drug Application and set a Prescription Drug User Fee Act goal date of November 27, 2023.

The approach allows investigators to assess post-vaccine response in immunocompromised patients who have received antibody prophylaxis.

Previous studies have shown promising results with liver or kidney transplants in patients with HIV, but there was a lack of literature regarding heart transplants specifically.